Literature DB >> 26682762

SLAM family receptors in normal immunity and immune pathologies.

Ning Wu1, André Veillette2.   

Abstract

The signaling lymphocytic activation molecule (SLAM) family is a group of six receptors restricted to hematopoietic cells. Most of these receptors are self-ligands, and thus are triggered in the context of interactions between hematopoietic cells. By way of their cytoplasmic domain, SLAM-related receptors associate with the SLAM-associated protein (SAP) family of adaptors, which control the signals and functions of SLAM family receptors. Recent findings have provided new insights into the key roles of SLAM family receptors in normal immunity, their involvement in human diseases and their usefulness as drug targets to treat human malignancies. These data are reviewed herein.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26682762     DOI: 10.1016/j.coi.2015.11.003

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  39 in total

Review 1.  Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.

Authors:  Sabarinath Venniyil Radhakrishnan; Neelam Bhardwaj; Tim Luetkens; Djordje Atanackovic
Journal:  Oncoimmunology       Date:  2017-03-28       Impact factor: 8.110

2.  Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus.

Authors:  Denis Comte; Maria P Karampetsou; Nobuya Yoshida; Katalin Kis-Toth; Vasileios C Kyttaris; George C Tsokos
Journal:  Arthritis Rheumatol       Date:  2017-05       Impact factor: 10.995

3.  SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.

Authors:  Jun Chen; Ming-Chao Zhong; Huaijian Guo; Dominique Davidson; Sabrin Mishel; Yan Lu; Inmoo Rhee; Luis-Alberto Pérez-Quintero; Shaohua Zhang; Mario-Ernesto Cruz-Munoz; Ning Wu; Donald C Vinh; Meenal Sinha; Virginie Calderon; Clifford A Lowell; Jayne S Danska; André Veillette
Journal:  Nature       Date:  2017-04-19       Impact factor: 49.962

4.  SAP and Lessons Learned from a Primary Immunodeficiency.

Authors:  Jennifer L Cannons; Pamela L Schwartzberg
Journal:  J Immunol       Date:  2017-09-01       Impact factor: 5.422

Review 5.  Natural killer cell cytotoxicity and its regulation by inhibitory receptors.

Authors:  Santosh Kumar
Journal:  Immunology       Date:  2018-04-11       Impact factor: 7.397

6.  Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.

Authors:  Jiro Kikuchi; Mitsuo Hori; Hidekatsu Iha; Noriko Toyama-Sorimachi; Shotaro Hagiwara; Yoshiaki Kuroda; Daisuke Koyama; Tohru Izumi; Hiroshi Yasui; Atsushi Suzuki; Yusuke Furukawa
Journal:  Leukemia       Date:  2019-07-29       Impact factor: 11.528

Review 7.  Elotuzumab as a novel anti-myeloma immunotherapy.

Authors:  Sabarinath Venniyil Radhakrishnan; Neelam Bhardwaj; Mary Steinbach; Janet Weidner; Tim Luetkens; Djordje Atanackovic
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

8.  X-Linked Lymphoproliferative Syndrome Presenting as Adult-Onset Multi-Infarct Dementia.

Authors:  Patrick R Blackburn; Wen-Lang Lin; David A Miller; Oswaldo Lorenzo-Betancor; Emily S Edwards; Michael T Zimmermann; Luca P Farrugia; William D Freeman; Alexandra I Soto; Ronald L Walton; Eric W Klee; Paldeep S Atwal; Roshini S Abraham; Daniel D Billadeau; Owen A Ross; Dennis W Dickson; James F Meschia
Journal:  J Neuropathol Exp Neurol       Date:  2019-05-01       Impact factor: 3.685

Review 9.  CAR T cell therapies for patients with multiple myeloma.

Authors:  Lekha Mikkilineni; James N Kochenderfer
Journal:  Nat Rev Clin Oncol       Date:  2020-09-25       Impact factor: 66.675

Review 10.  Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.

Authors:  He Huang; Heng-Wei Wu; Yong-Xian Hu
Journal:  J Zhejiang Univ Sci B       Date:  2020 Jan.       Impact factor: 3.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.